Welcome to our dedicated page for Iovance Biotherp news (Ticker: IOVA), a resource for investors and traders seeking the latest updates and insights on Iovance Biotherp stock.
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) is a biotechnology company focused on innovating, developing, and delivering tumor infiltrating lymphocyte (TIL) cell therapies for patients with cancer. This news page aggregates company announcements, clinical updates, regulatory developments, and financial disclosures related to Iovance’s TIL platform and commercial activities.
Readers can find news about Amtagvi, which Iovance describes as the first FDA-approved T cell therapy for a solid tumor indication, as well as updates on its use in advanced melanoma and other solid tumors. Coverage includes information on Health Canada’s conditional approval of Amtagvi for certain patients with unresectable or metastatic melanoma, and ongoing work to expand access through treatment centers and international markets.
The feed also features interim data from key clinical trials, such as registrational Phase 2 studies of lifileucel in advanced non-small cell lung cancer and other solid tumors, along with reports on next-generation programs like gene-edited TIL therapies and modified IL-2 analogs. Corporate news items include quarterly financial result announcements, conference presentations, equity inducement grants under Nasdaq Listing Rule 5635(c)(4), and capital markets transactions described in SEC filings.
Investors, analysts, and healthcare professionals can use this page to follow how Iovance communicates progress on its TIL pipeline, commercial execution for Amtagvi and Proleukin, and interactions with regulators. Regularly reviewing these updates provides context on the company’s development trajectory and its efforts to advance TIL-based immuno-oncology therapies.
Iovance Biotherapeutics, a late-stage biotechnology firm, will present at the BTIG Biotechnology Conference 2020 on August 11 at 2:30 PM ET. The event will focus on their T cell-based cancer immunotherapies, particularly Tumor Infiltrating Lymphocyte (TIL) therapy for solid tumors and blood cancers. The company is conducting pivotal studies in metastatic melanoma and advanced cervical cancer, and its TIL therapies are being explored for various cancers. A live webcast will be available on their investor website.
Iovance Biotherapeutics (NASDAQ: IOVA) reported its second quarter 2020 financial results, showing a cash position of $777.4 million as of June 30, compared to $312.5 million at the end of 2019. The net loss was $63 million or $0.47 per share, reflecting an increase from $47.6 million in Q2 2019. Clinical progress includes positive data from the melanoma program for lifileucel, supporting a planned BLA submission. Enrollment completed for cervical cancer studies, with ongoing preparations for commercial launch and CLL/SLL studies.
Iovance Biotherapeutics (NASDAQ: IOVA) will release its Q2 2020 financial results on August 6, 2020, followed by a conference call at 4:30 p.m. EDT. The company, focused on T cell-based cancer therapies, is advancing its pivotal studies for metastatic melanoma and advanced cervical cancer. Iovance’s Tumor Infiltrating Lymphocyte (TIL) therapy aims to leverage patients' own immune cells to combat cancer. The company is also exploring PBL therapy for blood cancers. More information can be found on their website.
Iovance Biotherapeutics announced its participation in two upcoming virtual conferences in June 2020. The company will present at the Goldman Sachs 41st Annual Global Healthcare Conference on June 11 at 3:00 p.m. ET and at the JMP Securities Hematology and Oncology Forum on June 18 at 2:20 p.m. ET. Live and archived webcasts will be accessible on the Iovance Investors website. Iovance focuses on T cell-based immunotherapies for treating solid tumors and blood cancers, including ongoing pivotal studies for metastatic melanoma and advanced cervical cancer.
Iovance Biotherapeutics has successfully closed a public offering of 19,475,806 shares at $31.00 per share, raising $603.7 million in gross proceeds. The company plans to utilize these funds for the potential commercial launch of lifileucel and LN-145 for advanced cancers, and to initiate registration for tumor infiltrating lymphocyte therapies in non-small cell lung cancer. The offering was conducted under a shelf registration statement that became effective on May 27, 2020.
Iovance Biotherapeutics announced a public offering of $500 million in common stock, all to be sold by the company. An additional 30-day option for underwriters to purchase up to $75 million of extra shares is also mentioned. Proceeds from the offering will support the potential commercial launch of lifileucel for advanced melanoma and LN-145 for cervical cancer, as well as ongoing clinical trials and general corporate purposes. The offering will utilize a shelf registration statement filed with the SEC.
Iovance Biotherapeutics (NASDAQ: IOVA) announced new interim data from Cohort 2 of the C-144-01 study of lifileucel for advanced melanoma, to be presented at ASCO 2020. As of February 2020, the median duration of response (DOR) remains unmeasured at a median follow-up of 17 months, with an overall response rate of 36.4% from 66 patients. The adverse event profile aligns with advanced disease and treatment regimens. The presentation will provide further insights into the durable effects of TIL therapy in heavily pretreated patients. Future updates are anticipated following the ASCO event.
Iovance Biotherapeutics (NASDAQ: IOVA) reported Q1 2020 results, posting a net loss of $69.6 million, or $0.55 per share, up from a net loss of $37.0 million, or $0.30 per share in Q1 2019. R&D expenses surged to $57.0 million due to increased clinical trials and licensing costs. The company held $251.2 million in cash at March 31, 2020. Iovance remains committed to commercializing TIL therapies for melanoma and cervical cancer, with pivotal study enrollments progressing ahead of schedule, and plans for a BLA submission in late 2020.
Summary not available.
Summary not available.